Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Theriva Biologics ( (TOVX) ) has issued an update.
On April 17, 2026, Theriva Biologics announced that new tumor response, biomarker and subgroup data from its VIRAGE Phase 2b clinical trial of VCN-01 plus gemcitabine/nab-paclitaxel in newly diagnosed metastatic pancreatic cancer will be presented in a poster session at the American Association for Cancer Research Annual Meeting in San Diego on April 20, 2026. The poster, led by Dr. Manuel Hidalgo of NYU Langone Health, details analyses from a randomized, open-label study comparing standard gemcitabine/nab-paclitaxel with and without intravenous VCN-01.
According to the released conclusions, patients treated with VCN-01 plus chemotherapy showed improved overall survival and progression-free survival versus chemotherapy alone, with later-emerging, higher-magnitude and more durable responses that suggest an immune-mediated mechanism of action. The benefit in overall survival was generally maintained across patient subgroups, including those with liver metastases, and appeared greater in patients receiving a second VCN-01 dose, reinforcing the potential of VCN-01 to enhance outcomes in metastatic pancreatic cancer and underpinning Theriva’s plans for a pivotal Phase 3 program in this indication.
The most recent analyst rating on (TOVX) stock is a Buy with a $1.00 price target. To see the full list of analyst forecasts on Theriva Biologics stock, see the TOVX Stock Forecast page.
Spark’s Take on TOVX Stock
According to Spark, TipRanks’ AI Analyst, TOVX is a Neutral.
Score is held down primarily by weak financial performance (no revenue, sustained losses and cash burn, and declining equity/assets), implying continued financing risk. Technicals are supportive in the short term but look overbought and remain below the 200-day trend. Corporate events add some upside from Phase 3 alignment and partnering, but warrant-approval delays introduce uncertainty; valuation metrics provide limited support due to negative earnings and no dividend.
To see Spark’s full report on TOVX stock, click here.
More about Theriva Biologics
Theriva Biologics, Inc. is a diversified clinical-stage biopharmaceutical company focused on developing therapeutics to treat cancer and related diseases with high unmet medical need. Its lead candidate, VCN-01 (zabilugene almadenorepvec), is an oncolytic adenovirus platform designed for intravenous, intravitreal and antitumoral delivery to degrade tumor stroma, enhance access of co-administered therapies and stimulate anti-tumor immune responses.
The company’s pipeline also includes SYN-004 (ribaxamase), an enzyme intended to degrade certain IV beta-lactam antibiotics in the gastrointestinal tract to protect the microbiome and reduce the incidence and severity of acute graft-versus-host disease in allogeneic hematopoietic cell transplant recipients. Theriva Biologics targets cancers such as pancreatic ductal adenocarcinoma, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer and retinoblastoma, aiming to improve outcomes in settings where current treatments are often ineffective.
Average Trading Volume: 12,614,776
Technical Sentiment Signal: Sell
Current Market Cap: $11.71M
Learn more about TOVX stock on TipRanks’ Stock Analysis page.